Veconomist the Vegan Business Magazine Stay Informed Stay Competative Get our Newsletter

« Previous article
Next-generation Swee...

17th July 2023  Content supplied by: Ark Biotech

Cultivated Meat's Path to Price Parity

Cultivated meat is at an inflection point. Companies are shifting focus from feasibility to unit economics and scale-up. We estimate that cultivated meat can reach a price of $29.5/lb with already commercialized technology and approaches, which is cost-competitive with whole cuts like filet mignons and tenderloins, but still 6x more expensive than ground beef. For cultivated meat to reach mass consumption, it must be cheaper.

Ark’s techno-economic analysis (TEA) demonstrates four ways to bring down the cost of goods sold (COGS) well below the $29.5/lb baseline:
  1. Reduce the cost of media
  2. Improve biomass yields
  3. Optimize the bioprocess
  4. Reduce capital spend (depreciation), primarily through larger bioreactors


Ark’s TEA is distinct in that it leverages achievements from industrial-cell culture to determine a baseline and models out COGS for a larger factory (50K MT of annual output) with larger bioreactors (up to 1M liters) and different modes of production (batch, fed-batch, perfusion, continuous). ‍

Key findings
  • $29.5/lb COGS is a baseline: Using known cell-culture achievements from the pharmaceutical industry provides a baseline upon which further price reduction can be achieved
  • No silver bullet: Advancements across media, bioreactors, cells, and bioprocess are all needed to reach price parity‍
  • Media is the biggest contributor to COGS: Reducing costs to ~$1/L in conjunction with other improvements can support cultivated meat reaching price parity‍
  • The biggest lever to reduce CapEx is increasing the size of bioreactors: Larger bioreactors also reduce COGS through lower depreciation and reduced labor needs‍
  • Cell density needs to match or exceed high-performing cell lines in the pharmaceutical industry
  • Differentiation can meaningfully improve unit economics: Impact will vary based on mass increase and speed of process‍
  • A fed-batch or continuous process is the most cost-effective: Fed-batch is superior in most cases, but continuous has the benefit of requiring less CapEx and needing a smaller footprint


To learn more - download the full version.

Have a question? Reach out to Ark Biotech using the green "Request Information" button.



Date Published: 17th July 2023

Source article link: View

View full company details

Related news